Roche Unit, Hansoh Strike License Deal for Antibody-drug Conjugate Programs

09:20 AM EDT, 10/19/2026 (MT Newswires) -- Roche Holding (ROG.SW) unit F. Hoffmann-La Roche signed a strategic collaboration and license agreement with three subsidiaries of Hansoh Pharmaceutical Group covering antibody-drug conjugate, or ADC, programs. The programs comprise two preclinical Hansoh ADC programs and multiple ones based on targets proposed by Roche, according to a Monday release. Hansoh will lead early development of the programs through the completion of phase 1a clinical trials and retain all rights to develop, register and commercialize the programs in mainland China, Hong Kong, Macau and Taiwan. Roche will be responsible for further development elsewhere. Under the deal, Hansoh will receive $400 million in upfront payment and a $110 million payment on the first anniversary. The Chinese company is eligible for potentially more than $15 billion in milestone payments.